What is a stock summary page? Click here for an overview.
Business Description

ContraFect Corp
NAICS : 325412
SIC : 2834
ISIN : US2123261024
Compare
Compare
Traded in other countries / regions
CFRXQ.USA22R.Germany Index Membership
Russell 2000 IPO Date
2014-09-12Description
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Financial Strength
Name | Current | Vs Industry | Vs History |
---|
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 14.29 | |||||
9-Day RSI | 30.27 | |||||
14-Day RSI | 38.25 | |||||
12-1 Month Momentum % | -99.44 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History |
---|
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
Name | Current | Vs Industry | Vs History |
---|
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | 0.09 | |||||
EV-to-EBITDA | 0.1 | |||||
Earnings Yield (Greenblatt) % | 1111.11 | |||||
FCF Yield % | -3560600 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CFRXQ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ContraFect Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -19.27 | ||
Beta | -7.19 | ||
3-Year Sharpe Ratio | -2.44 | ||
3-Year Sortino Ratio | -2.05 | ||
Volatility % | 125.66 | ||
14-Day RSI | 38.25 | ||
14-Day ATR ($) | 0.000019 | ||
20-Day SMA ($) | 0.000155 | ||
12-1 Month Momentum % | -99.44 | ||
52-Week Range ($) | 0.0001 - 0.03 | ||
Shares Outstanding (Mil) | 10.7 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 0 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ContraFect Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ContraFect Corp Stock Events
Event | Date | Price ($) | ||
---|---|---|---|---|
No Event Data |
ContraFect Corp Frequently Asked Questions
What is ContraFect Corp(CFRXQ)'s stock price today?
The current price of CFRXQ is $0.00. The 52 week high of CFRXQ is $0.03 and 52 week low is $0.00.
When is next earnings date of ContraFect Corp(CFRXQ)?
The next earnings date of ContraFect Corp(CFRXQ) is 2025-05-30 Est..
Does ContraFect Corp(CFRXQ) pay dividends? If so, how much?
ContraFect Corp(CFRXQ) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |